A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With Urothelial Carcinoma (KEYMAKER-U04): Master Protocol
Details
Age
Adult
Type of Study
Other
Locations
University of Colorado Hospital
Principal Investigator
Thomas Flaig, MD
Study ID
Protocol Number: 22-2055
More information available at ClinicalTrials.gov: NCT00000000
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers